#XtalPi
For those who haven’t seen it - Signet Therapeutics, which XtalPi incubated and partnered with on SIGX1094, was nominated for the Prix Galien USA Best Biotechnology Award for the program.

Full write-up: en.xtalpi.com/signet-thera...
Signet Therapeutics, Incubated by XtalPi, Nominated for 2025 Prix Galien USA Best Biotechnology Award for First-in-Class Diffuse Gastric Cancer Drug SIGX1094R – XtalPi
en.xtalpi.com
November 13, 2026 at 4:54 AM
SIGX1094 is a clinical-stage, first-in-class drug candidate for diffuse gastric cancer, an aggressive disease that's hard to model in the lab.

To study its biology, Signet and XtalPi used organoids that captured key disease features and tested AI-designed molecules against them.
November 13, 2026 at 4:52 AM
Laboratoires Pierre Fabre and XtalPi Announce Innovative Collaboration Leveraging AI for Drug Discovery#France#Drug_Discovery#Pierre_Fabre#XtalPi#Castres
Laboratoires Pierre Fabre and XtalPi Announce Innovative Collaboration Leveraging AI for Drug Discovery
Laboratoires Pierre Fabre and XtalPi have formed a strategic alliance to advance drug discovery, focusing on oncology and rare diseases using AI technologies.
third-news.com
November 9, 2026 at 9:51 AM
Pierre Fabre and XtalPi Announce AI-Powered Drug Discovery Partnership#France#Pierre_Fabre#AI_Drug_Discovery#XtalPi#Castres
Pierre Fabre and XtalPi Announce AI-Powered Drug Discovery Partnership
Pierre Fabre and XtalPi join forces in an innovative partnership utilizing AI technology for advanced drug discovery in oncology and rare diseases.
third-news.com
November 9, 2026 at 9:51 AM
Pierre Fabre and XtalPi Forge AI-Powered Collaboration to Enhance Drug Discovery#France#Drug_Research#Pierre_Fabre#XtalPi#Castres
Pierre Fabre and XtalPi Forge AI-Powered Collaboration to Enhance Drug Discovery
Laboratoires Pierre Fabre and XtalPi collaborate to leverage AI in identifying and developing new drug candidates, focusing on oncology and rare diseases.
third-news.com
November 9, 2026 at 9:52 AM
Laboratoires Pierre Fabre and XtalPi Team Up for AI-Powered Drug Discovery Innovations#France#Drug_Discovery#Pierre_Fabre#XtalPi#Castres
Laboratoires Pierre Fabre and XtalPi Team Up for AI-Powered Drug Discovery Innovations
Laboratoires Pierre Fabre and XtalPi have joined forces to innovate drug discovery using AI and robotics, focusing on areas with unmet medical needs.
third-news.com
November 9, 2026 at 9:51 AM
Recherche médicale : Pierre Fabre s'associe à XtalPi pour accélérer la découverte de médicaments grâce à l'IA
Recherche médicale : Pierre Fabre s'associe à XtalPi pour accélérer la découverte de médicaments grâce à l'IA
Les Laboratoires Pierre Fabre et l'entreprise XtalPi associent leurs expertises pour découvrir de nouvelles molécules thérapeutiques grâce à l'intelligence artificielle et à la robotique. Une collabor...
www.ladepeche.fr
November 9, 2026 at 2:49 PM
Few people have shaped #DrugDiscovery like Greg Verdine. The Harvard professor emeritus and DoveTree founder helped drug the cancer targets RAS(ON) and β-catenin, long considered “undruggable,” and founded more than a dozen biotech companies. We recently welcomed him to XtalPi.
November 10, 2026 at 4:06 PM
Pierre Fabre and XtalPi Agree to AI-Driven Drug Discovery Partnership

Basile Morin / CC BY-SA 4.0 Laboratoires Pierre Fabre and XtalPi announced a drug-discovery agreement in Castres, France, and Shenzhen, China, on November 9, combining AI and robotics with pharmaceutical research to seek new…
Pierre Fabre and XtalPi Agree to AI-Driven Drug Discovery Partnership
Basile Morin / CC BY-SA 4.0 Laboratoires Pierre Fabre and XtalPi announced a drug-discovery agreement in Castres, France, and Shenzhen, China, on November 9, combining AI and robotics with pharmaceutical research to seek new small-molecule treatments. The partnership focuses on oncology, with potential work in dermatology and rare diseases. The companies' announcement describes a research collaboration across multiple programmes, not a clinical-trial result or an approved medicine.
jbiznews.com
November 9, 2026 at 9:51 AM
The focus is difficult-to-drug targets, with potential to expand into dermatology and rare diseases. XtalPi will design and deliver molecules using its AI- and robotics-driven platform; Pierre Fabre will advance them. Terms include upfront, milestones and downstream participation.
November 9, 2026 at 2:03 PM
AI創薬のXtalPiが、革新的な次世代RNA創薬基盤「Kodexia™」を発表🧬

・世界初の生成AI×第一原理計算の融合プラットフォーム
・siRNAの配列設計〜検証を完全クローズドループ化
・難治性疾患向け核酸医薬の発見・最適化を劇的に加速

物理計算とAIの統合が、次世代バイオ創薬のボトルネックを打破する転換点になりそうです。

#AI創薬 #バイオテック #核酸医薬 #創薬
November 8, 2026 at 3:04 AM
XtalPi joins Tencent, Alibaba and SMIC in the top ten by weight of #HKEX’s new Artificial Intelligence Index.

The 40-company benchmark places #AIforScience, including drug discovery and biotechnology, alongside chips, infrastructure and foundation models.
November 5, 2026 at 4:42 PM
1/ What happens when regional medicinal knowledge meets AI-powered drug discovery? XtalPi and #DubaiMedicalUniversity are exploring that intersection in a new partnership.

#TraditionalMedicines are a key area of shared interest, alongside broader pharmaceutical research.
November 3, 2026 at 3:51 PM
XtalPi Holdings Limited announced its collaboration with the Materials Accelerator for Research, Venture & Enterprise Launchpad, led by Singapore's Agency for Science, Technology and Research.

Source: Vietnam Investment Review
XtalPi collaborates with ASTAR on AI materials discovery in Singapore
Technology firm XtalPi Holdings collaborated with Singapore's Agency for Science, Technology and Research under the MARVEL-AI initiative to accelerate artificial intelligence driven materials science research.
vir.com.vn
November 2, 2026 at 4:36 AM
XtalPi Partners with A*STAR under MARVEL-AI to Advance AI-Driven Materials Innovation

​ XtalPi joins industry and technology partners to support MARVEL-AI's mission to connect materials discovery with industrial deployment. The collaboration combines XtalPi's AI and laboratory automation…
XtalPi Partners with A*STAR under MARVEL-AI to Advance AI-Driven Materials Innovation
​ XtalPi joins industry and technology partners to support MARVEL-AI's mission to connect materials discovery with industrial deployment. The collaboration combines XtalPi's AI and laboratory automation capabilities with A*STAR's expertise in materials science, validation, and industrial translation. SINGAPORE, Oct. 29, 2026 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi," HKEX: 2228), an AI- and robotics-driven drug and materials discovery company, today announced its collaboration with the Materials Accelerator for Research, Venture & Enterprise Launchpad (MARVEL-AI).
ohsem.me
October 29, 2026 at 1:10 PM
Plastic recycling has stayed under 10% for decades, partly because durable plastics are hard to break down cleanly. New plastics developed by XtalPi-incubated FutureBio’s founders recover 93-96% of their triketone building blocks in 5 M HCl over 24-72 h at just 20-60 °C.
October 26, 2026 at 3:37 PM
PKU Life Sciences connected students with XtalPi, Bluepha, and MindFlow at the 9th Career Talk on Oct 12. The session focused on career paths in AI and biotech, with practical job search tips and face-to-face Q&A.
#PKU #SLSPKU #CareerTalk #AIBiotech #JobSearch
October 26, 2026 at 2:32 AM
99% yield and 92% ee at room temperature, with just 5 mol% catalyst. Getting high reactivity and high selectivity together is the challenge. XtalPi and SUSTech used computational design to achieve both.
October 22, 2026 at 6:42 PM
We've made lcms2yield available on GitHub - along with the code, model weights, and datasets. We hope others working on automated chemistry find it useful and build on it.

GitHub: github.com/xtalpi-inc/...
Paper: pubs.acs.org/doi/10.1021...

#AIforScience #OpenSource
GitHub - xtalpi-inc/lcms2yield
Contribute to xtalpi-inc/lcms2yield development by creating an account on GitHub.
github.com
October 15, 2026 at 3:06 PM
IgAN is the first of our six proprietary siRNA programs to reach PCC. We’re now advancing it toward clinical development and looking to work with pharma partners to bring more such therapies through discovery and development.

www.prnewswire.com/news-releas...

#AIforScience #siRNA #DrugDiscovery
XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation
Preclinical data demonstrate subnanomolar silencing potency, achieving an IC50 tens of times lower than the corresponding values for two clinical-stage...
www.prnewswire.com
October 16, 2026 at 3:15 PM
XtalPi Achieves Milestone with siRNA Candidate for IgA Nephropathy in Just Nine Months#USA#Cambridge#IgA_nephropathy#XtalPi_Holdings#siRNA_therapeutics
XtalPi Achieves Milestone with siRNA Candidate for IgA Nephropathy in Just Nine Months
XtalPi has successfully nominated its first siRNA preclinical candidate for IgA nephropathy, showcasing rapid AI-driven development in just nine months.
third-news.com
October 15, 2026 at 3:52 PM
Automated labs can run thousands of reactions. But every new product poses the same question: how much did we actually make? XtalPi is open-sourcing lcms2yield, an AI model integrated into our robotic labs that estimates yields without product-specific calibration curves. 🧵
October 15, 2026 at 3:06 PM
XtalPi moving from prediction models to end-to-end lab agents is a real shift for Chinese AI drug discovery. But "upgrade" is carrying weight here: no independent evals, no third-party reproduction. Hard to see this displacing wet-lab-plus-Schrödinger pipelines in regulated pharma until someone...
‘China’s Claude Science’ emerges: XtalPi completes major product upgrade for XtalPi Science
XtalPi announced a major upgrade to its XtalPi Science scientific-agent platform, adding more than 80 proprietary scientific skills and tools and linking them to autonomous laboratory robots. Internal tests claim better performance than Claude on several drug-discovery tasks.
aichina.news
October 13, 2026 at 4:49 PM
XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies
https://www.pressreleasecc.com/2026/10/02/xtalpi-advances-hair-loss-drug-program-into-ind-enabling-studies
www.pressreleasecc.com
October 11, 2026 at 11:12 AM